Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Core Viewpoint - Drugmakers are planning to increase prices on at least 350 branded medications, including vaccines for COVID, RSV, shingles, and the cancer treatment Ibrance, despite ongoing scrutiny from the Trump administration [1] Group 1: Price Increases - The planned price hikes will affect a wide range of medications, indicating a significant trend in the pharmaceutical industry towards higher costs for consumers [1] - Specific medications targeted for price increases include vaccines and well-known treatments, highlighting the impact on both public health and individual patients [1] Group 2: Regulatory Environment - The price increases come amid a backdrop of regulatory scrutiny from the Trump administration, which has been focused on drug pricing and healthcare costs [1] - The actions of drugmakers may provoke further discussions and potential regulatory responses regarding drug pricing practices in the U.S. [1]